Treatments for children and adolescents with AML

Kim, Hyery

doi:10.5045/br.2020.s002

Cited by 16 publications

(17 citation statements)

References 78 publications

(106 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hematopoietic stem cell transplantation (HSCT) is the mainstay therapy for malignant and benign hematological diseases like thalassemia major, aplastic anemia, leukemia, and metabolic diseases like Hurler syndrome. 1 , 2 , 3 Graft-versus-host disease (GVHD) is a clinical disease with multiple organ and system involvement due to the donor-derived T cells recognizing host antigens as foreign, and is the main cause of morbidity and mortality after HSCT. 4 Ocular involvement can occur as a manifestation of GVHD and is referred to as ocular GVHD.…”

Section: Introductionmentioning

confidence: 99%

Ocular Findings of Pediatric Dry Eye Related to Graft-Versus-Host Disease

Kızıltunç¹,

Büyüktepe²,

Yalçındağ³

et al. 2021

tjo

View full text Add to dashboard Cite

Objectives: To evaluate the frequency and findings of dry eye associated with ocular graft-versus-host disease (GVHD) in pediatric hematopoietic stem cell transplantation (HSCT) patients. Materials and Methods: Retrospectively the records of pediatric patients with ocular GVHD were evaluated and ophthalmologic examination findings as well as Schirmer test results, tear film break-up time, and corneal staining grades were recorded. In severe dry eye patients topical cyclosporine-A was prescribed and the results were evaluated. Results: GVHD was detected in 51 (23.4%) of 218 HSCT patients, 4 of whom died during follow-up. Thirty (63.8%) of the remaining 47 patients had chronic ocular GVHD and 4 patients with severe dry eye were treated with topical cyclosporine-A with a median follow-up of 12.1 months. Severe dry eye symptoms and findings significantly improved in 2 patients. However, 1 patient had to stop treatment due to side effects. Conclusion: In children, chronic ocular GVHD is a common finding of GVHD after HSCT. Therefore, these patients should be examined periodically for dry eye.

show abstract

Section: Introductionmentioning

confidence: 99%

Ocular Findings of Pediatric Dry Eye Related to Graft-Versus-Host Disease

Kızıltunç¹,

Büyüktepe²,

Yalçındağ³

et al. 2021

tjo

View full text Add to dashboard Cite

show abstract

“… 3 In recent decades, the overall survival (OS) rate of children with AML has remarkably increased due to the intensification of chemotherapy, allogeneic hematopoietic stem cell transplantation, and improvement in supportive care. 4 However, the outcomes of different biological subtypes of AML vary. 5 Moreover, primary refractory or relapsed pediatric AML, which accounts for 35–48% of pediatric AML cases in 5 years, 6–8 results in significant morbidity and mortality, and the long-term survival in patients with these features remains poor.…”

Section: Introductionmentioning

confidence: 99%

Netrin-1 inducing antiapoptotic effect of acute myeloid leukemia cells in a concentration-dependent manner through the Unc-5 netrin receptor B-focal adhesion kinase axis

Zhang

Zhu

et al. 2023

Cancer Biology & Therapy

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a hematological malignancy that commonly occurs in children. The prognosis of pediatric AML is relatively poor, thus threatening the patient’s survival. The aberrant expression of the axon guidance factor, netrin-1, is observed in various types of malignancies, and it participates in the proliferation and apoptosis of tumor cells. Herein, we aimed to explore the role of netrin-1 in AML cells. Netrin-1 is highly expressed in AML patients. Proliferation and anti-apoptosis were observed in AML cells treated with netrin-1. The interaction between netrin-1 and Unc-5 netrin receptor B (UNC5B) was detected through coimmunoprecipitation, and UNC5B ribonucleic acid interference restrained the influence of netrin-1 on the AML cells. The phosphorylation of focal adhesion kinase-protein kinase B (FAK-Akt) was upregulated in AML cells treated with netrin-1. Both FAK and Akt inhibitors abrogated the effects of netrin-1 on the proliferation and apoptosis of AML cells. In conclusion, netrin-1 could promote the growth and reduce the apoptosis of AML cells in a concentration-dependent manner, and that these effects were mediated by activating the FAK-Akt signaling pathway via the UNC5B.

show abstract

“…Pediatric acute myeloid leukemia (AML) is a heterogeneous group of diseases classified based on lineage, genetics, and morphology. Although AML accounts for only 15%–20% of children with acute leukemia, the overall survival (OS) rate is significantly poorer than that of acute lymphoblastic leukemia (ALL), and the relapse rate is as high as 34%–38% 1,2 . However, in recent years, with the advent of cytogenetic and molecular biology tests to provide a basis for risk stratification of pediatric AML and timely initiation of appropriate treatment, the survival rate of pediatric AML has been improved.…”

Section: Introductionmentioning

confidence: 99%

Clinical characteristics and prognosis analysis of patients with de novo ASXL1‐mutated AML treated with the C‐HUNAN‐AML‐15 protocol: A multicenter study by the South China Pediatric AML Collaborative Group

et al. 2023

View full text Add to dashboard Cite

Background: ASXL1 mutation is an independent prognostic factor in adult acute myeloid leukemia (AML), but its effect on the prognosis of pediatric AML is poorly understood.Aims: This study aimed to investigate the clinical characteristics and prognostic factors of ASXL1-mutant pediatric AML from a large Chinese multicenter cohort.Methods: A total of 584 pediatric patients with newly diagnosed AML from 10 centers in South China were enrolled. The exon 13 of ASXL1 was amplified by polymerase chain reaction (PCR), and then analyzed the mutation status of the locus. (n = 59 for ASXL1-mut group, n = 487 for ASXL1-wt group).Results: ASXL1 mutations were found in 10.81% of all patients with AML. A complex karyotype was significantly less common in the ASXL1-mut AML group than in the ASXL1-wt group (1.7% vs. 11.9%, p = 0.013). Furthermore, TET2 or TP53 mutations were predominantly found in the ASXL1+ group (p = 0.003 and 0.023, respectively). The 5-year overall survival (OS) and event-free survival (EFS) of the total cohort were 76.9% and 69.9%. In ASXL1-mut AML patients, a white blood cell (WBC) count ≥50 × 10 9 /L had significantly poorer 5-year OS and EFS than a WBC count <50 × 10 9 /L (78.0% vs. 44.6%, p = 0.001; 74.8% vs. 44.6%, p = 0.003, respectively), while receiving hematopoietic stem cell transplantation (HSCT) had a higher 5-year OS and EFS (84.5% vs. 48.5%, p = 0.024; 79.5% vs. 49.3%, p = 0.047, respectively). In the multivariate Cox regression analysis, patients with high-risk AML undergoing HSCT tended to have a better 5-year OS and EFS than those receiving chemotherapy as a consolidation (HR = 0.168 and 0.260, both p < 0.001), and WBC count ≥50 × 10 9 /L or failure to achieve complete | 13183 ZENG et al.

show abstract

Treatments for children and adolescents with AML

Cited by 16 publications

References 78 publications

Ocular Findings of Pediatric Dry Eye Related to Graft-Versus-Host Disease

Ocular Findings of Pediatric Dry Eye Related to Graft-Versus-Host Disease

Netrin-1 inducing antiapoptotic effect of acute myeloid leukemia cells in a concentration-dependent manner through the Unc-5 netrin receptor B-focal adhesion kinase axis

Clinical characteristics and prognosis analysis of patients with de novo ASXL1‐mutated AML treated with the C‐HUNAN‐AML‐15 protocol: A multicenter study by the South China Pediatric AML Collaborative Group

Contact Info

Product

Resources

About